Skip to content
DataLookout
Menu

PURENCT06886191

puO2 in RenalGuard Pilot Study

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words Show 4 more changesShow less
    • Completed without a posted recruiting period
    • Primary completion date changed from estimate of Dec 31, 2026 to Jun 12, 2026
    • Study sites: 0 to 1
    • Study completion date changed from estimate of Dec 31, 2026 to Jun 15, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Delta PuO2
Timeframe: Baseline (before start of surgery) to 45 minutes after start of CPB

Secondary (4)

Repeated PuO2
PuO2 AUC
PuO2 sub threshold
Diuresis and fluid balance

Arms and interventions

RenalGuard (RG)Experimental

The RG system is used to ensure neutral (0) fluid balance while maintaining a urine flow \>200 ml/hour. Urine output is replaced 1:1 with Plasmolyte solution. In patients randomized to RG, therapy is initiated after baseline measurements but before the start of surgery. If baseline urine flow is \< 200 ml/hour, a bolus dose of furosemide (20 mg iv) is given, and additional furosemide bolus and/or titration of continuous furosemide infusion may be given to maintain urine flow rate \>200ml/hour. After completed surgery, RG therapy continues until 3 hours after weaning from CPB

Standard of CareNo intervention

Conduct of cardiopulmonary bypass will be done according to local clinical practice

Devices: RenalGuard Therapy

Sites

1 site in 1 country

  • Department of Cardiothoracic Anesthesia and Intensive Care, Sahlgrenska University HospitalGothenburg, Sweden